Maladies inflammatoires de l'intestin [Main therapeutic advances in IBD in 2007].

Details

Serval ID
serval:BIB_60874DC11DF2
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Maladies inflammatoires de l'intestin [Main therapeutic advances in IBD in 2007].
Journal
Revue Médicale Suisse
Author(s)
Felley C., Mottet C., Maillard M.H., Hess J., Delarive J., Michetti P.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2008
Volume
4
Number
141
Pages
200, 202-4, 206-8 passim
Language
french
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Abstract
In 2008 three biological agents against TNFalpha will be available. The combination of infliximab with azathioprine is no longer recommended, as hepatosplenic lymphomas with a particularly bad prognosis have been associated with this combined therapy. Regular maintenance therapy with infliximab is as effective in preventing the development of anti-infliximab antibodies as co-administration of this anti-TNFalpha agent with an immunomodulator. The benefit of regular maintenance therapy is probably linked to the presence of residual trough levels of infliximab between perfusions.
Keywords
Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative/drug therapy, Crohn Disease/drug therapy, Crohn Disease/surgery, Humans, Immunoglobulin Fab Fragments/therapeutic use, Immunologic Factors/therapeutic use, Irritable Bowel Syndrome/drug therapy, Polyethylene Glycols/therapeutic use, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Pubmed
Create date
29/01/2009 22:12
Last modification date
20/08/2019 14:17
Usage data